CRT

JenaValve’s Trilogy THV System Highlighted at CRT 2024

Retrieved on: 
Tuesday, March 19, 2024
Observational study, CRT, Conference, Herpetology, Disease, Aortic regurgitation, Patient, Aortic stenosis, Treatment, TAVR, Trilogy, THV, Aorta

IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the Cardiovascular Research Technologies (CRT) Conference 2024.

Key Points: 
  • IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced highlights from the Cardiovascular Research Technologies (CRT) Conference 2024.
  • JenaValve’s Trilogy THV system, a TAVR system designed to treat patients with symptomatic, severe aortic regurgitation (ssAR), and symptomatic, severe aortic stenosis (ssAS), was featured in multiple scientific sessions highlighting the significant unmet need for devices to treat ssAR.
  • This session reviewed an observational study examining outcomes of patients with ssAR treated with off-label THV’s versus a device designed to treat ssAR.
  • Results showed significantly better technical and device success in the Trilogy arm, with significantly less valve embolization, need for a second valve, and post-procedural aortic regurgitation.

CLOVER CARBON EXCHANGE Launches "Clover Infinity" App to Promote Sustainable Living

Retrieved on: 
Monday, March 18, 2024
Carbon, CRT, Philosophy, CIT, CCE, Organic, App Store (iOS/iPadOS), Behavior, Google Play, Ecosystem, IOS, Android

New York, NY, March 18, 2024 (GLOBE NEWSWIRE) -- In efforts to advance global sustainability, CLOVER CARBON EXCHANGE (CCE) announces the launch of its innovative app, "Clover Infinity."

Key Points: 
  • New York, NY, March 18, 2024 (GLOBE NEWSWIRE) -- In efforts to advance global sustainability, CLOVER CARBON EXCHANGE (CCE) announces the launch of its innovative app, "Clover Infinity."
  • CLOVER CARBON EXCHANGE (CCE) has been a crucial player in global carbon neutrality efforts through carbon trading, but its mission extends beyond to creating a sustainable ecosystem.
  • Paul Newman, Chief Strategic Officer of CLOVER CARBON EXCHANGE, stated, "We believe that everyone's small steps can aggregate into global strides."
  • CLOVER CARBON EXCHANGE believes in the capacity for everyone to effect change, and Clover Infinity is the key to unlocking that potential.

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

Retrieved on: 
Wednesday, March 13, 2024
Blood pressure, CRT, Investigational device exemption, HOPE, Patient, Inflammation, Stroke, Gold, Restenosis, ISR, Medtronic, Beat (music), Trial of the century, Virtue, Sirolimus, Stent, Safety, Pharmacokinetics, SAB, Hypertension, Molecular mass, Food, Medical device

A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.

Key Points: 
  • A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure.
  • The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.
  • Specifically, the presented PK data showed that:
    Molecular weight of Sostenocel remained unchanged prior to elimination, showing no evidence of in-vivo degradation.
  • AVIM therapy demonstrated:
    Consistent favorable hemodynamic effects using both conduction system, as well as traditional right ventricular lead placements.

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

Retrieved on: 
Friday, April 5, 2024
Research, FDA, Clinical Trials, Biometrics, Health, Pharmaceutical, General Health, Science, Oncology, Lung cancer, Chemoradiotherapy, CRT, Small-cell carcinoma, Radiation, AstraZeneca, Survival, NSCLC, Immunotherapy, Disease, Infection, Carcinoma, Incidence, Progression-free survival, Patient, Warning, Doctor of Philosophy, Prednisone, Adrenocorticotropic hormone, Creatinine, Prognosis, PFS, Recurrence, ACTH, Administration, Pneumonitis, SCLC, Vaccine

Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.

Key Points: 
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.
  • Immune-mediated adrenal insufficiency occurred in 1.5% (6/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (0.3%) adverse reactions.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Retrieved on: 
Monday, March 11, 2024
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Cardiology, Registry, CRT, Aortic stenosis, TVT, Patient, Journal, Stroke, Mortality, Ultra, Oakland University, MD, Cardiovascular disease, American College, TAVR, Arrest, JACC, PVL, Medical imaging

Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.
  • In a second study presented during the late-breaking clinical trials session, small Edwards SAPIEN TAVR valves demonstrated equally excellent outcomes at 3 years as compared to larger SAPIEN TAVR valve sizes.
  • The study found that all Edwards TAVR platforms demonstrated excellent PVL results.
  • An analysis of 8,100 propensity matched patients across more than 800 sites in the United States found that patients treated with a 20mm Edwards SAPIEN valve demonstrated excellent all-cause mortality and stroke outcomes at 3-years, equivalent to those receiving 23, 26 and 29mm SAPIEN valve sizes.

Saranas Reveals Groundbreaking SAFE-MCS Study Results at CRT 2024

Retrieved on: 
Monday, March 11, 2024
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, CRT, Aortic stenosis, Physician, Risk, Early, Patient, Percutaneous coronary intervention, Henry Ford Health, MCS, PROTECT, Morristown Medical Center, Henry Ford, PCI, Bleeding, EVAR, Safety, Structural heart disease, TAVR, FDA

“This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.

Key Points: 
  • “This study is the first of its kind to specifically evaluate bleeding complications in patients undergoing protected PCI, with independently adjudicated results.
  • The Saranas Early Bird Bleed Monitoring System is the first and only FDA-approved device for real-time monitoring of endovascular bleed complications.
  • “We would like to thank the excellent team of physicians and coordinators who contributed to the success of this study,” commented Mike MacKinnon, CEO and President of Saranas.
  • Saranas is dedicated to establishing a new benchmark for bleed detection during and after endovascular procedures, with the goal of improving patient outcomes and decreasing healthcare expenses overall.”

Nymbl Systems to Debuts its HME Intuitive Software Solutions at Medtrade 2024

Retrieved on: 
Thursday, March 21, 2024
Automation, CRT, Health, Optimism, Medtrade, Agility, Artificial intelligence, Growth, HME, Online shopping

DUBLIN, Ohio, March 21, 2024 /PRNewswire-PRWeb/ -- Nymbl Systems, a software company dedicated to delivering better business outcomes for those who enable better health and mobility, announced today that the company will be featuring its intuitive HME software next week at the industry's largest tradeshow, Medtrade 2024, booth #1227. Through the use of leading-edge technology and years of experience supporting the complex billing workflows for O&P and CRT providers, Nymbl is bringing its solutions to the HME market.

Key Points: 
  • DUBLIN, Ohio, March 21, 2024 /PRNewswire-PRWeb/ -- Nymbl Systems , a software company dedicated to delivering better business outcomes for those who enable better health and mobility, announced today that the company will be featuring its intuitive HME software next week at the industry's largest tradeshow, Medtrade 2024 , booth #1227.
  • Nymbl leverages cutting-edge technology, like artificial intelligence (AI) and cloud-based computing, to deliver more agile and intuitive software solutions that support higher levels of automation, flexibility, and accessibility than existing billing and business management solutions on the market.
  • In addition to powerful software solutions, Nymbl has an A+ rating for customer service and responsiveness among its more than 250+ customers.
  • The Nymbl HME software will be on display in booth #1227 at Medtrade 2024.

Conformal Medical's CLAAS® System Demonstrates Low Thrombogenicity Compared to Commercially Available LAAO Devices

Retrieved on: 
Wednesday, March 13, 2024
Foam, CRT, Thomas Jefferson University, DRT, Patient, Thrombosis, PET, Abstract (summary), Polytetrafluoroethylene, CLASS, JACC: Cardiovascular Interventions, Watchman, Safety, CLAAS, Medical device

NASHUA, N.H., March 13, 2024 /PRNewswire/ -- Conformal Medical, Inc. announced that the CLAAS® System was featured in a podium presentation at the Cardiovascular Research Technologies (CRT) 2024 conference. Dr. William Gray, Professor of Medicine, Thomas Jefferson University, System Chief, Cardiovascular Diseases at Main Line Health, and Co-Director Lankenau Heart Institute presented "Comparative Acute Thrombogenicity of The CLAAS Foam Implant and Watchman FLX In An In Vitro Blood Loop Model" during the conference's Best Abstracts, March 10th.

Key Points: 
  • An in vitro study compared the relative thrombogenicity of the CLAAS implant to the Watchman FLX device.
  • The CLAAS design features a foam cup with an embedded nitinol skeleton covered by a fluoropolymer (ePTFE) cover.
  • Three of each device (n=3) were inserted into an acute radiolabeled in vitro blood loop system.
  • Conformal Medical is actively enrolling patients in the CONFORM pivotal trial, evaluating the safety and efficacy of the CLAAS System compared to other commercially available LAAO devices.

Steel Partners Holdings Reports Fourth Quarter and Full Year Results

Retrieved on: 
Friday, March 8, 2024
Professional Services, Finance, ERP, Tax, Financial services, Investment, Service provider, Supply, Adjustment, Supply chain, Capital expenditure, CRT, Public expenditure, Energy, Corporation, Partnership, Cryptocurrency

The Company recorded asset impairment charges of $0.5 million and $0.3 million for the three months ended December 31, 2023 and 2022, respectively.

Key Points: 
  • The Company recorded asset impairment charges of $0.5 million and $0.3 million for the three months ended December 31, 2023 and 2022, respectively.
  • The Company recorded asset impairment charges of $0.9 million and $3.2 million for the twelve months ended December 31, 2023 and 2022, respectively.
  • As of December 31, 2023, total debt was $191.4 million, an increase of $11.0 million, as compared to December 31, 2022.
  • As of December 31, 2023, net cash totaled $56.4 million, an increase of $104.0 million, as compared to December 31, 2022.